P
Passage Bio, Inc. (PASG)
NCM – Real Time Price. Currency in USD
4.70
+0.37 (8.55%)
At close: Jun 26, 2026, 4:00 PM EDT
4.56
-0.14 (-2.90%)
After-hours: Jun 26, 2026, 7:46 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
4.70
+0.37 (8.55%)
At close: Jun 26, 2026, 4:00 PM EDT
4.56
-0.14 (-2.90%)
After-hours: Jun 26, 2026, 7:46 PM EDT
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding β-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington’s disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania’s Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
| Name | Position |
|---|---|
| Mr. Stuart M. Henderson | Chief Business Officer |
| Ms. Kathleen Borthwick | Senior VP, CFO, Principal Financial Officer & Principal Accounting Officer |
| Date | Type | Document |
|---|---|---|
| 2026-06-24 | 425 | tm2618476d3_425.htm |
| 2026-05-27 | 8-K | pasg-20260521x8k.htm |
| 2026-05-26 | 8-K | tm2615548d1_8k.htm |
| 2026-05-12 | 10-Q | pasg-20260331x10q.htm |
| 2026-04-28 | 8-K | tm2612859d1_8k.htm |
| 2026-04-20 | 8-K | tm2612152d1_8k.htm |
| 2026-04-07 | DEFA14A | pasg-20260407xdefa14a.htm |
| 2026-04-07 | ARS | pasg-20251231xars.pdf |
| 2026-03-10 | 8-K | tm268398d1_8k.htm |
| 2026-03-04 | S-8 | tm267647d1_s8.htm |